Association study between COMT , DRD2 , and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

• Published in: Neuropsychiatric disease and treatment Vol. 14; pp. 2981 - 2987
• Main Authors: Escamilla, Raul, Camarena, Beatriz, Saracco-Alvarez, Ricardo, Fresán, Ana, Hernández, Sandra, Aguilar-García, Alejandro
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2018; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Analysis; Antipsychotic agents; Antipsychotics; Digital divide; Dopamine; Dopamine receptors; Drug dosages; Drug therapy; Enzymes; Genes; Genetic aspects; Genetic markers; Genetic polymorphisms; Genetic research; Genotype & phenotype; Mental disorders; Original Research; Patients; Pharmacogenetics; Pharmacogenomics; Phenols (Class of compounds); Phenotypes; Polymorphism; Psychiatry; Psychotropic drugs; resistant to treatment; Schizophrenia; Single nucleotide polymorphisms; Studies; Systematic review; Trifluoperazine; ultra-resistant to treatment; Mexico; dopamine; ultraresistant to treatment; pharmacogenetics; resistant to treatment
• ISSN: 1176-6328; 1178-2021; 1178-2021
• DOI: 10.2147/NDT.S176455

The efficacy of schizophrenia treatments using antipsychotics (APs) has long been established, but the benefit obtained by several patients using conventional APs (typical or atypical) has not been enough. Currently, the genetic study of the primary mechanisms of action of the APs has been focused on the dopaminergic pathways. The objective of this study was to determine if the response phenotypes (responder, resistance to treatment, and ultra-resistance to treatment groups) are associated with six single-nucleotide polymorphisms: (Val158Met), (A-241G, C376G, C939T, Taq1A), and (Ser9Gly). We classified the patients through a retrospective/prospective methodology to define response phenotypes. /Val158Met and /Ser9Gly were associated with the responder group ( <0.05). The single-nucleotide polymorphism A-241G of gene was related with the resistant-to-treatment group ( <0.001). Finally, Met/Met of and Ser/Gly of genes showed a predictive effect associated with the resistant-to-treatment phenotype. Further analyses should be performed to validate these genetic markers as mediators for the response to APs.